ArticlePloS one2026
Antifungal efficacy of microencapsulated oligoDNAs through whey protein concentrate (WPC) as coated protein against Verticillium dahliae.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Verticillium dahliae is a devastating soil-borne fungal pathogen causing wilting in over 400 plant species, leading to significant economic losses. While nucleic acid-based biocontrol strategies like dsRNA-induced consistent with gene-silencing activity show promise, their application is hindered by poor environmental stability and high production costs. Double-stranded oligodeoxynucleotides (oligoDNAs) offer a stable and cost-effective alternative, but require efficient delivery systems. This study aimed to develop and evaluate the efficacy of novel antifungal microcapsules, encapsulating oligoDNAs (targeting the Clp-1 and HiC-15 genes of V. dahliae) within a whey protein concentrate (WPC) matrix via electrospraying, for controlling Verticillium wilt. The physicochemical properties of the microcapsules were characterized using SEM, TEM, DLS, FTIR, XRD, TGA, DSC, and BET. Antifungal activity was assessed through in vitro colony growth assays and fluorescence microscopy to visualize oligoDNA uptake. In planta efficacy was evaluated on tomato seedlings by calculating the Disease Index (DI) and Area Under the Disease Progress Curve (AUDPC) over 30 days. Characterization confirmed the successful formation of spherical, oligoDNA-loaded WPC microcapsules with enhanced thermal stability. In vitro, the encapsulated oligoDNA (oligoDNA159 + 166) significantly inhibited fungal colony growth compared to controls, while WPC alone showed no effect. Fluorescence microscopy revealed that Cy3-labeled oligoDNA associated with fungal hyphae, producing discrete punctate signals consistent with cellular uptake, though definitive confirmation of intracellular localization requires higher-resolution imaging techniques. In the greenhouse trial, the encapsulated oligoDNA treatment exhibited the strongest suppression, with a mean DI of 50 (± 10.0) on day 30, corresponding to a 47% reduction compared to the pathogen control. This study demonstrates that WPC-encapsulated oligoDNA is an effective, sustainable, and specific biocontrol agent against V. dahliae. The dual mode of action-direct inhibition of fungal growth and potential host-induced resistance-positions this technology as a promising, environmentally friendly strategy for managing vascular wilt diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.